INKmune™ is a biologic delivery system that allows for the delivery of essential priming signals to patients’ resting NK cells. INKmune™ is delivered by a simple IV infusion. Once in the patient’s system, INKmune™ comes in contact with resting NK cells. The interaction converts NK cells to “primed NK cell” (PiNK) similar to an “on-off” switch. PiNK then remain primed until they contact and kill cancer cells.
What is INKmune™?
INmune Bio has discovered a way to deliver priming as a simple intravenous infusion. The priming delivery system is call INKmune™. INKmune™ is a patented biologic that is produced by a master cell bank using well-established manufacturing techniques.
Are NK cell-directed therapeutic strategies important for the control of cancer?
Yes, the most clinically effective immunotherapy programs for cancer are focused helping NK cells. For example, Riuximab™ and Herceptin™ are currently the world’s largest selling immunotherapy drugs and both are both monoclonal antibodies targeting tumor antigens. These therapeutic anti-cancer antibodies do not kill cancer cells on their own, they require NK cells to bind the fragment crystallizable (FC) portion of the antibody for effective cancer killing. Put another way, INKmune™ helps NK cells target and kill the tumor cell using a different method than these anti-cancer monoclonal antibodies, but with the same results. Unlike Riuximab™ and Herceptin™, INKmune is not antigen-specific so there is no need to identify the specific tumor antigen.